Zhitong Finance App News, Jianshi Technology-B (09877) announced that the company's transducer tricuspid valve replacement system LUX-Valve Plus has recently obtained approval from the Department of Health of the Hong Kong Special Administrative Region of the People's Republic of China, and the company is actively promoting the commercialization of this product in Hong Kong, China.

LUX-VALVEPLUS is the world's second approved in-situ tricuspid valve replacement product via catheter. Lux-Valve Plus has been widely recognized by the market thanks to the product's differentiated advantages, ongoing therapy promotion work, and rich clinical application experience. LUX-ValvePlus has now obtained registration approval in many countries and regions such as Europe, the Middle East, and Asia Pacific. This time, LUX-ValvePlus was approved by the Hong Kong Department of Health, further validating the product's potential for treating tricuspid valve reflux. The company will continue to fully accelerate the global commercialization process of LUX-Valve Plus to further achieve the company's long-term strategic goals.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.